Spots Global Cancer Trial Database for metastatic gastric cancer
Every month we try and update this database with for metastatic gastric cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | NCT05024812 | Metastatic Gast... | fruquintinib＋to... | 18 Years - 75 Years | The First Affiliated Hospital of Zhengzhou University | |
| The Association Between Alpha 1 Acid Glycoprotein Level and Outcome Metastatic Cancer Treated With Docetaxel | NCT01814150 | Metastatic Lung... Metastatic Brea... Metastatic Gast... Metastatic Pros... Metastatic Blad... | 18 Years - | Meir Medical Center | ||
| Study Evaluating Neurotoxicity in Patients With Metastatic Gastro Intestinal Cancer Taking Phycocare® or Placebo During Oxaliplatin Based Chemotherapy | NCT05025826 | Metastatic Gast... | Phycocare Placebo | 18 Years - | Nantes University Hospital | |
| Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients | NCT01063517 | Gastric Cancer | olaparib paclitaxel Placebo | 18 Years - 130 Years | AstraZeneca | |
| Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin® in Healthy Male Volunteers | NCT05765357 | Metastatic Brea... Metastatic Gast... | Trastuzumab for... Herceptin | 18 Years - 65 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Genotype Guided Chemotherapy in Gastric Cancer Patients | NCT02204306 | Metastatic Gast... | TSER | 18 Years - 70 Years | Central South University | |
| An Open Label, Prospective, Multicentre, Non-interventional Study of Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer | NCT02668380 | Metastatic Gast... | 18 Years - | Peking Union Medical College Hospital | ||
| Histone Deacetylases - Gastric Cancer (HDAC-GaCa-2008) | NCT01528501 | Metastatic Gast... | Panobinostat (L... | 18 Years - 90 Years | Technical University of Munich | |
| Peri-operative Zimberelimab (Anti-PD-1) vs Zimberelimab in Combination With Domvanalimab (Anti-TIGIT) in Resectable Mismatch Repair Deficient/Micro-satellite Unstable Gastric and Gastro-oesophageal Junctional Adenocarcinoma (ZODIAC) | NCT06250036 | Metastatic Esop... Metastatic Gast... | Single agent zi... Combination zim... | 18 Years - | Royal Marsden NHS Foundation Trust | |
| Histone Deacetylases - Gastric Cancer (HDAC-GaCa-2008) | NCT01528501 | Metastatic Gast... | Panobinostat (L... | 18 Years - 90 Years | Technical University of Munich | |
| Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer | NCT01084330 | Advanced Gastri... Gastro-esophage... | AUY922 Docetaxel Irinotecan | 18 Years - | Novartis | |
| Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer | NCT00253370 | Adenocarcinoma ... Metastatic Gast... Advanced Unrese... | BAY 43-9006 docetaxel cisplatin | 18 Years - | National Cancer Institute (NCI) | |
| Metronomic Chemotherapy in Advanced Gastric Cancer | NCT02855788 | Metastatic Gast... Locally Advance... | Paclitaxel 60mg... | 18 Years - 70 Years | Huashan Hospital | |
| Study of OB-002 in Patients With Refractory Metastatic Cancer | NCT05940844 | Metastatic Canc... Metastatic Colo... Metastatic Panc... Metastatic Gast... Metastatic Brea... Metastatic Urot... | OB-002 | 18 Years - | Orion Biotechnology Polska Sp. z o.o. | |
| Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | NCT05024812 | Metastatic Gast... | fruquintinib＋to... | 18 Years - 75 Years | The First Affiliated Hospital of Zhengzhou University | |
| Genotype Guided Chemotherapy in Gastric Cancer Patients | NCT02204306 | Metastatic Gast... | TSER | 18 Years - 70 Years | Central South University | |
| Improving the Approach to and Management of the Older Patient With Metastatic Gastric Cancer | NCT04618809 | Metastatic Gast... | Didactic Sessio... Comprehensive G... | 70 Years - | Fox Chase Cancer Center | |
| Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer | NCT00130689 | Esophageal Canc... Gastric Cancer Neoplasm Metast... | Cetuximab | 18 Years - | Dana-Farber Cancer Institute | |
| Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction | NCT04263870 | Gastroesophagea... Stomach Adenoca... Locally Advance... Metastatic Gast... | sintilimab | 18 Years - 75 Years | Sichuan University | |
| Histone Deacetylases - Gastric Cancer (HDAC-GaCa-2008) | NCT01528501 | Metastatic Gast... | Panobinostat (L... | 18 Years - 90 Years | Technical University of Munich | |
| WaKING: Wnt and checKpoint INhibition in Gastric Cancer | NCT04166721 | Metastatic Esop... Metastatic Gast... | Atezolizumab | 18 Years - | Royal Marsden NHS Foundation Trust | |
| A Trial of RAD001/Capecitabine in Refractory Gastric Cancer | NCT01099527 | Metastatic Gast... | Everolimus (RAD... Capecitabine | 18 Years - | Samsung Medical Center | |
| An Open Label, Prospective, Multicentre, Non-interventional Study of Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer | NCT02668380 | Metastatic Gast... | 18 Years - | Peking Union Medical College Hospital | ||
| A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer | NCT06251973 | Metastatic Esop... Advanced Unrese... Metastatic Gast... Metastatic Gast... Metastatic Esop... Metastatic Esop... Metastatic Gast... Metastatic Gast... Unresectable Es... Unresectable Es... Unresectable Ga... Unresectable Ga... Unresectable Ga... | AgenT-797 Botensilimab Balstilimab Ramucirumab Paclitaxel | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer | NCT00253370 | Adenocarcinoma ... Metastatic Gast... Advanced Unrese... | BAY 43-9006 docetaxel cisplatin | 18 Years - | National Cancer Institute (NCI) | |
| Histone Deacetylases - Gastric Cancer (HDAC-GaCa-2008) | NCT01528501 | Metastatic Gast... | Panobinostat (L... | 18 Years - 90 Years | Technical University of Munich | |
| International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer | NCT02065765 | Metastatic Gast... Metastatic Aden... | Ramucirumab | 18 Years - | Eli Lilly and Company | |
| Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer | NCT05859477 | Metastatic Gast... PD-L1 Gene Ampl... FGFR2 Amplifica... | Nivolumab Capecitabine Oxaliplatin | 18 Years - | Kidney Cancer Research Bureau | |
| GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study | NCT03751761 | Metastatic Gast... | durvalumab, tre... | 19 Years - | Asan Medical Center | |
| Home Parenteral Nutrition for Malnourished Unresectable Stage IV Gastric Cancer | NCT03121807 | Metastatic Gast... | Oliclinomel N4 ... Oxaliplatin 5Fluorouracil Leucovorin | 20 Years - 80 Years | Kaohsiung Medical University Chung-Ho Memorial Hospital | |
| Clinical Outcome of Palliative Surgery After Translational Therapy for Metastatic Gastric Cancer Versus Maintenance Chemotherapy for Metastatic Gastric Cancer | NCT05230771 | Metastatic Gast... Surgery Chemotherapy | Palliative surg... Chemotheraoy al... | 18 Years - 75 Years | Fujian Medical University | |
| TEW-7197 With Paclitaxel for the Treatment of Metastatic Gastric Cancer | NCT03698825 | Metastatic Gast... | TEW-7197 | 19 Years - | MedPacto, Inc. | |
| Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer | NCT00130689 | Esophageal Canc... Gastric Cancer Neoplasm Metast... | Cetuximab | 18 Years - | Dana-Farber Cancer Institute | |
| Low-Tox Vs Eox In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer | NCT02076594 | Locally Advance... Metastatic Gast... | Docetaxel Epirubicin Oxaliplatin Capecitabine | 18 Years - | Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente | |
| Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | NCT05024812 | Metastatic Gast... | fruquintinib＋to... | 18 Years - 75 Years | The First Affiliated Hospital of Zhengzhou University | |
| Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin® in Healthy Male Volunteers | NCT05765357 | Metastatic Brea... Metastatic Gast... | Trastuzumab for... Herceptin | 18 Years - 65 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Study of OB-002 in Patients With Refractory Metastatic Cancer | NCT05940844 | Metastatic Canc... Metastatic Colo... Metastatic Panc... Metastatic Gast... Metastatic Brea... Metastatic Urot... | OB-002 | 18 Years - | Orion Biotechnology Polska Sp. z o.o. | |
| Triplet Combination of Cytotoxics as First-line Treatment for Metastatic Gastric Cancer | NCT04358354 | Metastatic Gast... | Irinotecan Oxaliplatin 5-fluorouracil | 18 Years - 75 Years | Sixth Affiliated Hospital, Sun Yat-sen University | |
| The Association Between Alpha 1 Acid Glycoprotein Level and Outcome Metastatic Cancer Treated With Docetaxel | NCT01814150 | Metastatic Lung... Metastatic Brea... Metastatic Gast... Metastatic Pros... Metastatic Blad... | 18 Years - | Meir Medical Center | ||
| Peri-operative Zimberelimab (Anti-PD-1) vs Zimberelimab in Combination With Domvanalimab (Anti-TIGIT) in Resectable Mismatch Repair Deficient/Micro-satellite Unstable Gastric and Gastro-oesophageal Junctional Adenocarcinoma (ZODIAC) | NCT06250036 | Metastatic Esop... Metastatic Gast... | Single agent zi... Combination zim... | 18 Years - | Royal Marsden NHS Foundation Trust | |
| Triplet Combination of Cytotoxics as First-line Treatment for Metastatic Gastric Cancer | NCT04358354 | Metastatic Gast... | Irinotecan Oxaliplatin 5-fluorouracil | 18 Years - 75 Years | Sixth Affiliated Hospital, Sun Yat-sen University | |
| TEW-7197 With Paclitaxel for the Treatment of Metastatic Gastric Cancer | NCT03698825 | Metastatic Gast... | TEW-7197 | 19 Years - | MedPacto, Inc. | |
| Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric Cancer | NCT02537171 | Gastric Cancer | apatinib | 18 Years - | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | |
| Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma | NCT03409848 | Gastric Cancer Esophageal Canc... Adenocarcinoma ... HER2 Positive G... Metastatic Gast... GastroEsophagea... | Nivolumab Nivolumab Ipilimumab | 18 Years - | AIO-Studien-gGmbH | |
| The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer | NCT03154983 | Metastatic Gast... | docetaxel | 18 Years - 70 Years | Zhongnan Hospital | |
| A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors | NCT05143970 | Metastatic Canc... Metastatic Brea... Metastatic Panc... Metastatic Gast... Metastatic Lung... Metastatic Ovar... Oesophageal Can... Endometrial Can... Advanced Solid ... | IPH5301 ALONE O... | 18 Years - | Institut Paoli-Calmettes | |
| GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study | NCT03751761 | Metastatic Gast... | durvalumab, tre... | 19 Years - | Asan Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
